Business
PacBio Announces Second Quarter 2025 Financial Results
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second
About this update from Pacific Biosciences Of California, Inc.
[{"type":"text","content":"MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results: Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release. GAAP gross profit for the second quarter of 2025 was $14.7 million compared to $5.9 million for the second quarter of 2024. Non-GAAP gross profit for the second quarter of 2025 was $15.2 million compared to $13.2 million for the second quarter of 2024 and a non-GAAP gross margin of 38% in the second quarter of 2025 compared to 37% for the second quarter of 2024. GAAP operating expenses totaled $59.5 million for the second quarter of 2025, compared to $181.8 million for the second quarter of 2024. Non-GAAP operating expenses totaled $58.1 million for the second quarter of 2025, compared to $71.0 million for the second quarter of 2024. GAAP and non-GAAP operating expenses for the second quarter of 2025 and the second quarter of 2024 included non-cash share-based compensation of $11.0 million and $16.1 million, respectively. GAAP net loss for the second quarter of 2025 was $41.9 million, compared to $173.3 million for the second quarter of 2024. Non-GAAP net loss for the second quarter of 2025 was $40.0 million, compared to $55.2 million for the second quarter of 2024. GAAP net loss per share for the second quarter of 2025 was $0.14, compared to $0.64 for the second quarter of 2024. Non-GAAP net loss per share for the second quarter of 2025 was $0.13, compared to $0.20 for the second quarter of 2024. Updates since PacBio's last earnings release Published the Platinum Pedigree benchmark in Nature Methods, the most known comprehensive family-based variant dataset to date, developed using PacBio HiFi sequencing. The benchmark improves AI-based variant calling accuracy and establishes a new standard for e...